Predicting ovarian function during breast cancer treatment
Part of Cancer, Skin clinical trials.
This study looks at how a hormone called AMH changes during breast cancer treatment to help predict how well your ovaries are working as you approach menopause. It may help doctors better understand fertility and ovarian health for women in your situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman between 45 and 55 years old.
- Have hormone receptor-positive breast cancer (a type that uses hormones to grow).
- Be perimenopausal: you had a period within the last 3 months and certain hormone levels (FSH and E2) are within the study's range.
- Be about to start chemotherapy and/or hormone therapy.
- Be willing to have extra blood draws and keep a diary of your periods.
- Not have had both ovaries removed, not have had pelvic radiation, and not be currently pregnant or planning pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This study is looking for genetic markers that may help predict how chemotherapy affects the ovaries. It's for women who had breast cancer or lymphoma, froze their ovarian tissue before treatment, and finished that treatment at least 6 months ago.
This study looks at how certain blood markers relate to ovarian function in women with normal ovaries, diminished ovarian reserve (DOR), or primary ovarian insufficiency (POI). It may help doctors better understand these conditions.
This study looks at DNA changes to understand the cause of premature ovarian insufficiency (early menopause). It may help clarify what’s happening in your body and guide future care.
This study looks at menopause symptoms in women who have had their ovaries removed as part of gynecologic cancer treatment. It aims to understand how these symptoms affect patients over time.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.